Profluent Bio Valuation, Funding & Investors

Biossil is an applied AI drug discovery platform that develops specialized treatments for individual patients.

Adept AI is a San Francisco-headquartered AI research lab developing models that automate software tasks using natural language instructions. Its ACT-1 platform enables developers to build applications through browser-based actions, competing with robotic process automation via foundation models trained on code and interfaces.

Aibee develops artificial intelligence solutions specializing in computer vision, speech recognition, natural language processing, and robotics for vertical industries including retail, finance, and healthcare. Beijing-headquartered and founded in 2017, the company partners with Alibaba Cloud and serves clients like China Resources Vanguard, deploying AI systems that process over 10 million daily transactions in smart retail applications.

Amperity is a Seattle-headquartered customer data platform that unifies profiles across online and offline touchpoints using AI-driven identity resolution. The system ingests data from sources like Shopify, Salesforce, and loyalty programs, creating actionable 360-degree views for brands including Patagonia and Nestlé. Amperity enables personalized marketing campaigns and loyalty programs without custom engineering.

BenevolentAI is a London-headquartered clinical-stage company using artificial intelligence for drug discovery, listed on Euronext Amsterdam under BAI. Its platform supports 13 named programs and over 10 exploratory ones, with collaborations including AstraZeneca on respiratory and cardiovascular diseases. Facilities in Cambridge and New York enable wet-lab validation of AI-generated candidates.

Eve is a San Francisco-headquartered legal AI platform for law firms. Launched in 2023, it automates case intake, document review, drafting, and e-discovery using GPT models fine-tuned on legal corpora. Eve processes 1 million+ pages monthly for mid-sized practices handling personal injury and employment cases. Compatible with Clio and PracticePanther, it operates in all US states.

Haomo.AI is a Beijing-headquartered autonomous driving technology company, formerly Haomo Zhixing. It develops NOA systems deployed in vehicles from partners like Changan Automobile and GAC Aion. Haomo.AI's solutions include perception software, mapping, and planning algorithms for L2+ to L4 autonomy levels tested on public roads across China.

Hasura is a San Francisco and Bangalore-based provider of the Hasura GraphQL Engine, an open-source tool that generates instant GraphQL APIs over Postgres databases and other data sources. Launched in 2018, it enables real-time subscriptions, fine-grained access control, and integrations with services like Kafka and BigQuery. The company offers Hasura Cloud for managed deployments and serves enterprises building backend APIs.

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

Kakao Enterprise is a Seongnam-headquartered provider of enterprise AI, cloud, and collaboration platforms, established in 2019 as a Kakao subsidiary. The company delivers Kakao Work corporate messenger, iCloud storage, and AI engines to sectors like healthcare, finance, and construction. Based in Pangyo Techno Valley, Kakao Enterprise supports digital transformation with data analytics and API services for over 10,000 business clients in South Korea.

Orca Bio is a Menlo Park-headquartered clinical-stage cell therapy company engineering allogeneic T-cell products for blood cancers and autoimmune diseases. Its OrcaTropic platform purifies precise cell doses from donors, advancing phase 1/2 trials for lymphoma and multiple sclerosis at centers like Stanford. Orca Bio targets over 100 indications with automated manufacturing.

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

CStone Pharmaceuticals is engaged in developing and commercializing of immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment.

Tchaikapharma Highquality Medicines AD is engaged in the business of manufacturing and selling pharmaceuticals in Bulgaria. The company specializes in both generic and in-licensed manufacturing. The company has medicines for Anaesthetics, Nervous system, Oncology, Anti-Inflammatory and Anti-Rheumatic, Antibiotics, Digestive system, diabetes and metabolism, and Respiratory system. The company generates all of its revenue from the sale of medicines. Geographically, the company generates the majority of its revenue from Bulgaria.

Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.